Cytogenix (fka CYGX)

[djharker]

>It could the very thing that was making finances difficult for several reasons.

Could anyone expand on this thesis? Why would the Hunt's getting 10% of future revenues be a dealblocker for financing? I can see why if the percentage was larger, but 10%?

There is speculation/assumption here that this buy-back of the 10% is somehow related to financing. I am not convinced - no one here knows, so this is guessing, not fact.

I think the fundamental issue for financing will be to convince the potential investor(s) that the science will make it thru FDA drug testing Phases. That's how the investor(s) will see a return on their investment - drug licensing agreements. Whether 90% or 100% of those big $$ licensing agreements makes it to CYGX seems much less important than whether those revenues will ever EXIST or not.